Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;53(10):4252-7.
doi: 10.1128/AAC.00208-09. Epub 2009 Jul 27.

Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

Affiliations

Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

O Murillo et al. Antimicrob Agents Chemother. 2009 Oct.

Abstract

Since the currently approved dose of daptomycin (6 mg/kg of body weight/day) has been associated with clinical failures and resistance development, higher doses for some difficult-to-treat infections are being proposed. We studied the efficacy of daptomycin at high doses (equivalent to 10 mg/kg/day in humans) and compared it to that of reference and alternative treatments in a model of foreign-body infection with methicillin (meticillin)-resistant Staphylococcus aureus. In vitro studies were conducted with bacteria in the log and stationary phases. For the in vivo model, therapy with daptomycin at 100 mg/kg/day, vancomycin at 50 mg/kg/12 h, rifampin (rifampicin) at 25 mg/kg/12 h, or linezolid at 35 mg/kg/12 h was administered for 7 days. Antibiotic efficacy was evaluated using either bacteria from tissue cage fluids or those attached to coverslips. We screened for the emergence of linezolid- and rifampin-resistant strains and analyzed the surviving population from the daptomycin-treated group. Only daptomycin was bactericidal in both the log- and stationary-phase studies. Daptomycin (decrease in the log number of CFU per milliliter of tissue cage fluid, 2.57) and rifampin (decrease, 2.6 log CFU/ml) were better (P < 0.05) than vancomycin (decrease, 1.1 log CFU/ml) and linezolid (decrease, 0.9 log CFU/ml) in the animal model. Rifampin-resistant strains appeared in 60% of cases, whereas no linezolid resistance emerged. No daptomycin-resistant subpopulations were detected at frequencies of 10(-7) or higher. In conclusion, daptomycin at high doses proved to be as effective as rifampin, and the two were the most active therapies for this experimental foreign-body infection. These high doses ensured a profile of safety from the development of resistance.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Time-kill curves for log-phase (A) and stationary-phase (B) bacteria with clinically representative drug concentrations (in micrograms per milliliter). Abbreviations: DAP, daptomycin; RIF, rifampin; LNZ, linezolid; VAN, vancomycin; CTRL, controls.

Similar articles

Cited by

References

    1. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681. - PubMed
    1. Baldoni, D., M. Haschke, Z. Rajacic, W. Zimmerli, and A. Trampuz. 2009. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53:1142-1148. - PMC - PubMed
    1. Bassetti, M., F. Vitale, G. Melica, E. Righi, B. A. Di, L. Molfetta, F. Pipino, M. Cruciani, and D. Bassetti. 2005. Linezolid in the treatment of Gram-positive prosthetic joint infections. J. Antimicrob. Chemother. 55:387-390. - PubMed
    1. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. - PMC - PubMed
    1. Berger-Bachi, B., A. Strassle, and F. H. Kayser. 1986. Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur. J. Clin. Microbiol. 5:697-701. - PubMed

Publication types

MeSH terms